Article Per Year (5 Year)
p-Index From 2021 - 2026
0.751
P-Index
This Author published in this journals
All Journal Jurnal Kefarmasian AKFARINDO Indonesian Journal of Pharmacy and Natural Product Clinical and Pharmaceutical Sciences Journal
Prita Anggraini Kartika Sari
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Social Sciences

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
PENGGUNAAN OBAT IMUNOSUPRESAN PADA PASIEN RAWAT INAP DI RSUD SLEMAN PERIODE 2019-2021 Affifatu Annisa; Woro Supadmi; Prita Anggraini Kartika Sari
Jurnal Kefarmasian Akfarindo Vol 10 No 1 (2025)
Publisher : Akademi Farmasi Indonesia Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37089/jofar.vi0.1094

Abstract

Imunosupresan atau penekan sistem imun adalah obat yang bekerja dengan menekan disregulasi sistem imun dalam tubuh. Pemilihan obat imunosupresan disesuaikan dengan tingkat keparahan dan manifestasi penyakit. Pada penyakit tertentu seperti autoimun perlu diberikan obat imunosupresan. Penggunaan obat imunosupresan perlu diperhatikan karena dapat meningkatkan resiko infeksi dan efek samping yang merugikan pada pasien. Tujuan penelitian ini adalah untuk mengetahui gambaran karakteristik demografi pasien, karakteristik penyakit, dan karakteristik obat imunosupresan yang digunakan pasien rawat inap di RSUD Sleman periode 2019-2021. Penelitian ini merupakan penelitian non-eksperimental bersifat deskriptif dengan pengumpulan data retrospektif dari catatan rekam medik. Teknik pengambilan sampel menggunakan purposive sampling. Analisis data dilakukan secara deskriptif dalam bentuk persentase karakteristik demografi pasien, karakteristik penyakit, dan karakterstik obat. Hasil penelitian diperoleh 73 rekam medik dengan data demografi pasien meliputi pasien dengan jenis kelamin perempuan (68,5%), kelompok usia 45-59 tahun (38,3%), status pendidikan menengah (52,1%), pasien tidak bekerja (63,0%), pasien menikah (75,3%), dan jenis pembayaran BPJS Kesehatan (94,5%). Karakteristik penyakit meliputi kanker (52,1%), anemia aplastic (24,7%), dermatitis alergi (16,4%). Karakterstik obat meliputi golongan obat kortikosteroid (86,3%), metilprednisolon (47,9%), dosis obat metilprednisolon 2x sehari 125 mg/vial (15,1%), bentuk sediaan injeksi (63%), dengan rute pemberian intravena (63%). Golongan obat persentase tertinggi adalah kortikosteroid, dengan jenis obat metilprednisolon. Bentuk sediaan injeksi dengan rute meberian secara intravena. Dosis obat metilprednisolon 2xsehari 125 mg/vial.
Analisis Efektivitas Regimen Terapi Antiretroviral terhadap Status Viral Load pada Pasien HIV di Puskesmas Umbulharjo 1 dan Gedongtengen: Effectiveness Analysis of Antiretroviral Therapy Regimens on Viral Load Status Among HIV Patients at Umbulharjo 1 and Gedongtengen Community Health Centers Prita Anggraini Kartika Sari; Risa Widiastuti; Nida Amalia Azmi
Indonesian Journal of Pharmacy and Natural Product Vol. 8 No. 01 (2025): Indonesian Journal of Pharmacy and Natural Product
Publisher : Universitas Ngudi Waluyo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35473/ijpnp.v8i01.4001

Abstract

Human Immunodeficiency Virus (HIV) remains a major public health challenge, including in the Special Region of Yogyakarta. This study compares the effectiveness of two first-line antiretroviral therapy (ART) regimens, namely TLD (Tenofovir-Lamivudine-Dolutegravir) and TLE (Tenofovir-Lamivudine-Efavirenz), in reducing viral load among HIV patients at two community health centers. A retrospective cohort design using convenience sampling was conducted based on medical records from Gedongtengen Community Health Center (January 2021–June 2023) and Umbulharjo 1 Community Health Center (January 2021–December 2022). Inclusion criteria comprised adult patients (≥17 years) who received TLD or TLE for at least six months and had complete viral load data. Statistical analyses (chi-square test, odds ratio) were performed on 102 patients (mean age 28.94 ± 9.98 years; 90.2% male). The majority (96.1%) were in early stages (1–2) of HIV infection, and 6.9% had opportunistic infections. Viral load suppression was achieved in 52% of patients receiving TLD compared to 21% in the TLE group (p = 0.015; OR = 3.01). The superior efficacy of TLD is attributed to Dolutegravir’s mechanism as an integrase inhibitor with a high barrier to resistance. Despite some limitations, these findings support prioritizing TLD as the preferred first-line ART regimen, particularly for patients in early stages of HIV infection.   ABSTRAK Human Immunodeficiency Virus (HIV) menjadi tantangan utama kesehatan masyarakat, termasuk di Daerah Istimewa Yogyakarta. Penelitian ini membandingkan efektivitas dua regimen terapi antiretroviral (ART) lini pertama, yaitu TLD (Tenofovir-Lamivudine-Dolutegravir) dan TLE (Tenofovir-Lamivudine-Efavirenz) dalam menurunkan viral load pasien HIV di dua puskesmas. Metode yang digunakan yaitu kohort retrospektif dengan convenience sampling dilakukan pada rekam medis di Puskesmas Gedongtengen (Januari 2021–Juni 2023) dan Puskesmas Umbulharjo 1 (Januari 2021–Desember 2022). Kriteria inklusi meliputi pasien dewasa (≥17 tahun) yang menerima TLD/TLE minimal selama 6 bulan dan memiliki data viral load lengkap. Analisis statistik (chi-square, odds ratio) dilakukan pada 102 pasien (rerata usia 28,94 ± 9,98 tahun; 90,2% laki-laki). Sebanyak 96,1% berada pada stadium awal (1–2) dan 6,9% mengalami infeksi oportunistik. Penekanan viral load tercapai pada 52% pasien penerima TLD, dibandingkan 21% pada TLE (p = 0,015; OR = 3,01). Keunggulan TLD diduga disebabkan oleh mekanisme Dolutegravir sebagai penghambat integrase dengan high resistance barrier. Meskipun memiliki keterbatasan, temuan ini mendukung prioritas TLD sebagai regimen ART lini pertama, khususnya bagi pasien stadium awal HIV.
In Silico Evaluation of Black Cumin Oil Constituents for Selective Anti-Inflammatory Inhibitor of COX-2 And 5-LOX Mufidah, Syarifatul; Putri Rachma Novitasari; Prita Anggraini Kartika Sari; Hani Badriyah Hidayati
Indonesian Journal of Pharmacy and Natural Product Vol. 8 No. 02 (2025): Indonesian Journal of Pharmacy and Natural Product
Publisher : Universitas Ngudi Waluyo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35473/ijpnp.v8i02.4420

Abstract

Black cumin oil (Nigella sativa) is widely known for its anti-inflammatory properties, attributed to various bioactive compounds. This study aimed to evaluate the binding affinity and selectivity of five major compounds from black cumin oil: dithymoquinone, thymoquinone, thymohydroquinone, p-cymene, and thymol, against key inflammatory enzymes: COX-1, COX-2, and 5-LOX, using an in silico approach. All compounds were assessed for drug-likeness using Lipinski’s Rule of Five before molecular docking with AutoDock Vina. Celecoxib, a selective COX-2 inhibitor, was used as a reference compound. Dithymoquinone demonstrated strong binding affinity to COX-2 (-9.3 kcal/mol) and 5-LOX (-8.4 kcal/mol), comparable to celecoxib (-9.9 and -8.3 kcal/mol, respectively), while showing lower affinity for COX-1 (-7.5 kcal/mol). The interaction analysis revealed hydrogen bonds and van der Waals forces with several active site residues, suggesting a stable and selective interaction. Other compounds showed moderate to high affinity but lacked the same degree of selectivity due to their interaction with COX-1. These findings indicate that dithymoquinone has the potential to act as a selective anti-inflammatory agent with a reduced risk of gastrointestinal side effects commonly associated with non-selective NSAIDs. The results support further investigation of dithymoquinone in preclinical and clinical settings to validate its efficacy and safety.
Potential Drug–Drug Interactions in Antihypertensive Therapy Among Outpatients with Comorbidities: Prevalence, Severity, and Clinical Implications Prita Anggraini Kartika Sari; Rahayu, Ade Rahmawati; Noor Faridah, Imaniar; Supadmi, Woro; Sari, Andriana; Ahmed, Bilal
Clinical and Pharmaceutical Sciences Journal Vol. 2 No. 1 (2026)
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/clips.v2i1.563

Abstract

Hypertension is a condition that frequently coexists with comorbidities, often necessitating polypharmacy and consequently increasing the risk of drug-drug interactions (DDIs). This study aimed to analyze the pattern and severity of potential DDIs among hypertensive outpatients with comorbidities at North Lombok Regional General Hospital in 2024. This study employed a descriptive observational design with retrospective data collection. A total of 100 outpatient medical records meeting the criteria were selected via probability sampling from the hospital database during January to December 2024. Among the included patients, 50% were aged >60 years, 60% were female, and 91% were covered by the National Health Insurance. Potential DDIs were assessed using the Drugs.com drug interaction checker and categorized based on severity into major, moderate, and minor. A total of 257 potential DDI events were identified, consisting of 19 major interactions (7.4%), 205 moderate interactions (79.8%), and 33 minor interactions (12.8%). The most frequent major interaction was the combination of spironolactone and candesartan, which poses a significant risk of hyperkalemia and hypotension. Moderate interactions were predominantly observed with the combination of furosemide and bisoprolol, which may increase the risk of hyperglycemia and hypertriglyceridemia. Meanwhile, the most frequent minor interaction was aspirin with bisoprolol, which may reduced beta-blocker antihypertensive effect. In conclusion, this study found that moderate severity potential DDIs were the most prevalent and could significantly impact therapeutic outcomes in hypertensive patients with comorbidities. These findings highlight the critical role of clinical pharmacists in identifying and mitigating clinically significant interactions through rigorous prescription monitoring, patient education, and optimization of drug therapy. Strengthened monitoring and evaluation of drug regimens are recommended to minimize the risk of adverse drug reactions and enhance patient safety.
Co-Authors Affifatu Annisa Ahmed, Bilal Andriana Sari Hani Badriyah Hidayati Imaniar Noor Faridah Mufidah, Syarifatul Nida Amalia Azmi Novitasari, Putri Rachma Rahayu, Ade Rahmawati Risa Widiastuti Woro Supadmi Woro Supadmi